Rnz: Our Changing World

In September 2022, two New Zealand patients became the first in the world to participate in a phase 1 clinical trial testing a new therapy for a rare neurogenetic condition called myotonic dystrophy. Claire Concannon learns about the trial, and how a new Neurogenetic Registry and Biobank covering 70 conditions is helping to connect New Zealand patients with international research.